Free shipping on all orders over $ 500

Pevonedistat

Cat. No. M2189

All AbMole products are for research use only, cannot be used for human consumption.

Pevonedistat Structure
Synonym:

MLN4924; MLN-4924

Size Price Availability Quantity
10mM*1mL in DMSO USD 97  USD97 In stock
1mg USD 45  USD45 In stock
5mg USD 100  USD100 In stock
10mg USD 159  USD159 In stock
25mg USD 278  USD278 In stock
50mg USD 448  USD448 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Pevonedistat (MLN4924) is a potent and selective, first-in-class inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy. MLN4924 (3 μM) inhibits overall protein turnover by <9% in HCT-116 cells. MLN4924 induces an alternative mechanism of action. Treatment of ABC DLBCL cells with MLN4924 resulted in rapid accumulation of pIkappaBalpha, decrease in nuclear p65 content, reduction of nuclear factor-kappaB (NF-kappaB) transcriptional activity, and G(1) arrest, ultimately resulting in apoptosis induction, events consistent with potent NF-kappaB pathway inhibition. Expression of UBA3 A171T is sufficient to decrease MLN4924 sensitivity of naive HCT116 cells, indicating that it is a dominant suppressor of MLN4924-mediated cell death.

In vivo administration of Pevonedistat (MLN4924) to mice bearing human xenograft tumors of ABC- and GCB-DLBCL blocked NAE pathway biomarkers and resulted in complete tumor growth inhibition. In primary human tumor models of ABC-DLBCL, Pevonedistat (MLN4924) treatment resulted in NF-kappaB pathway inhibition accompanied by tumor regressions.

Product Citations
Customer Product Validations & Biological Datas
Source Plos One (2018). Figure6. MLN4924 (Abmole Bioscience)
Method Western blot
Cell Lines CRBN KO cells
Concentrations 0.1 μM
Incubation Time 24 hrs
Results The BK currents were significantly decreased in CRBN-depleted cells compared to isogenic WT cells, and the difference was largely offset by treating the mutant cells with MLN4924
Source Plos One (2018). Figure5. MLN4924 (Abmole Bioscience)
Method Western blot
Cell Lines CRBN KO glioma cells
Concentrations 0.2 μM
Incubation Time 24 hrs
Results Likewise, treatment with proteasome or neddylation inhibitors in CRBN KO glioma cells could also increase the Slo1 levels, though treatment with bortezomib or MLN4924 in WT cells for excessive time led to decreased Slo1 levels, likely due to compound cytotoxicity
Source Oncol Lett (2018). Figure 3. MLN4924
Method immunofluorescence
Cell Lines EC1 and Kyse450 cells
Concentrations 0.0, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.0 μM
Incubation Time 72 h
Results MLN4924 treatment increased the level of CDT1 and ORC1 proteins in a dose.dependent manner.
Protocol (for reference only)
Cell Experiment
Cell lines HCT-116 cells
Preparation method Cell viability assay. Cell suspensions were seeded at 3,000–8,000 cells per well in 96-well culture plates and incubated overnight at 37℃. Compounds were added to the cells in complete growth media and incubated for 72 h at 37℃. Cell number was quantified using the ATPlite assay (PerkinElmer).
Concentrations 0~100µM
Incubation time 72h
Animal Experiment
Animal models Female athymic NCR Mice bearing HCT-116 xenografts
Formulation 10% cyclodextrin
Dosages 10,30 or 60mg/kg
Administration subcutaneously
Chemical Information
Molecular Weight 443.52
Formula C21H25N5O4S
CAS Number 905579-51-3
Solubility (25°C) DMSO ≥ 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Toth JI, et al. Cell Rep. A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924.

[2] Lin JJ, et al. Cancer Res. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells.

[3] Milhollen MA, et al. Blood. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.

[4] Soucy TA, et al. Nature. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Related NEDD8-activating Enzyme Products
ZM223 

ZM223 is a potent non-covalent NEDD8 activating enzyme (NAE) inhibitor, orally active.

ZM223 hydrochloride

ZM223 hydrochloride is a potent, orally active, non-covalent NEDD8 activating enzyme (NAE) inhibitor.

NAE-IN-M22

NAE-IN-M22 is a potent, selective, and reversible inhibitor of NEDD8-activating enzyme (NAE) in the micromolar range. In addition, NAE-IN-M22 inhibits the growth of various cancer cells and induces apoptosis in A549 cells.

TAS4464 hydrochloride

TAS4464 (hydrochloride) is a highly potent and selective inhibitor of NEDD8 activating enzyme (NAE), with an IC50 of 0.955 nM.

Pevonedistat hydrochloride

Pevonedistat hydrochloride (MLN4924 hydrochloride) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor, with an IC50 of 4.7 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Pevonedistat, MLN4924; MLN-4924 supplier, NEDD8-activating Enzyme, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.